Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized blinded trial of recombinant herpes zoster vaccine LZ901 in adults ≥50 years
ChiCTR2300079076Phase 3Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of LZ901 in herpes zoster (HZ) (2 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Proportion of participants achieving gE-specific CD4+/CD8+ T-cell responses. Started Dec 2023; status: completed.
02
Drugs
LZ901
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on ChiCTR2300079076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079076.